INFINITY PHARMACEUTICALS, INC. (INFI) is a publicly traded company in the Unknown sector. Across all available filings, 34 corporate insiders have executed 338 transactions totaling $693.5M, demonstrating a bearish sentiment with -$280.5M in net insider flow. The most recent transaction on Sep 12, 2023 involved a sale of 410,196 shares valued at $28.7K.
No significant insider buying has been recorded for INFI in the recent period.
No significant insider selling has been recorded for INFI in the recent period.
Based on recent SEC filings, insider sentiment for INFI is bearish with an Insider Alignment Score of 30/100 and a net flow of -$280.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at INFINITY PHARMACEUTICALS, INC. (INFI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 34 insiders are actively trading INFI stock, having executed 338 transactions in the past 90 days. The most active insider is Medical Co L.p. Rosebay (Executive), who has made 3 transactions totaling $312.7M.
Get notified when executives and directors at INFI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Q. Perkins Adelene | Executive | Sale | 410,196 | $0.07 | $28.7K | 10b5-1 |
| Sep 9, 2023 | Q. Perkins Adelene | Executive | Option Exercise | 768,133 | $N/A | $0 | 10b5-1 |
| Aug 2, 2022 | Peluso Stephane | Executive | Option Exercise | 50,000 | $N/A | $0 | |
| Aug 2, 2022 | Peluso Stephane | Executive | Sale | 14,994 | $0.66 | $9.9K | |
| Jun 16, 2022 | Schwartz Brian | Executive | Award | 30,919 | $0.68 | $21.0K | |
| Jun 16, 2022 | B. Evnin Anthony | Executive | Award | 46,378 | $0.68 | $31.5K | |
| Jun 10, 2021 | B. Evnin Anthony | Executive | Award | 3,061 | $3.43 | $10.5K | |
| Jun 10, 2021 | W. Beier David | Executive | Award | 3,061 | $3.43 | $10.5K | |
| May 14, 2021 | C. Selby Norman | Executive | Option Exercise | 5,000 | $0.92 | $4.6K | |
| Feb 11, 2021 | Bvf Inc/il | Executive | Sale | 1,215,491 | $5.37 | $6.5M | Large |
| Feb 11, 2021 | Bvf Inc/il | Executive | Sale | 152,127 | $5.37 | $816.9K | Large |
| Feb 11, 2021 | Bvf Inc/il | Executive | Sale | 892,467 | $5.37 | $4.8M | Large |
| Jan 22, 2021 | Fund L. P. Biotechnology Value | Executive | Sale | 2,458,838 | $4.14 | $10.2M | Large |
| Jan 22, 2021 | Fund L. P. Biotechnology Value | Executive | Sale | 2,821,663 | $4.14 | $11.7M | Large |
| Jan 22, 2021 | Fund L. P. Biotechnology Value | Executive | Sale | 568,019 | $4.14 | $2.4M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 49 | $487.0M | 69.9% |
Purchase(P) | 153 | $206.5M | 29.6% |
Exercise(M) | 46 | $3.2M | 0.5% |
Award(A) | 76 | $474.9K | 0.1% |
Other(J) | 11 | $0 | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Insider selling pressure at INFINITY PHARMACEUTICALS, INC. has increased, with 34 insiders executing 338 transactions across all time. Total sales of $487.0M significantly outpace purchases of $206.5M, resulting in a net outflow of $280.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.